Comparative Pharmacokinetics Study of the Leutragin Peptide Drug in Svetlogorsk Minipig Blood Serum after Single Administration

In this work, we investigate the pharmacokinetics of a new anti-inflammatory hexapeptide registered under the name of Leutragin. The study was conducted on Svetlogorsk minipigs by intravenous and a single rectal administration of the drug in the form of a solution and suppositories at an equal dose of 10 mg. The shortest time to reach peak concentration was demonstrated with intravenous administration, with the Tmax being 30 min. The maximum concentration (Cmax) when administering Leutragin in a suppository form was 141.37 ng/g. This concentration was achieved at the Tmax of 90 min, following which Leutragin remained in the bloodstream for 2.5 h. The absolute bioavailability of Leutragin in the suppository and solution form was 59.6% and 70.03%, respectively. The peak concentration of Leutragin under its rectal administration occurred at 150 min, following with the drug remained in the bloodstream for 4 h.